$2.34T
Total marketcap
$90.37B
Total volume
BTC 50.00%     ETH 15.40%
Dominance

Paradigm Biopharmaceuticals PBIGF Stock

0.17 USD {{ price }} 0.000000% {{change_pct}}%
Exchange
Other OTC
Market Cap
65.41M USD
LOW - HIGH [24H]
0.17 - 0.17 USD
VOLUME [24H]
80K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-0.15 USD

Paradigm Biopharmaceuticals Price Chart

Paradigm Biopharmaceuticals PBIGF Financial and Trading Overview

Paradigm Biopharmaceuticals stock price 0.17 USD
Previous Close 0.61 USD
Open 0.61 USD
Bid N/A x N/A
Ask N/A x N/A
Day's Range 0.61 - 0.61 USD
52 Week Range 0.61 - 1.36 USD
Volume 144 USD
Avg. Volume 517 USD
Market Cap 172.36M USD
Beta (5Y Monthly) 1.140996
PE Ratio (TTM) N/A
EPS (TTM) -0.15 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

PBIGF Valuation Measures

Enterprise Value 88.91M USD
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 4449.8228
Price/Book (mrq) 2.340996
Enterprise Value/Revenue 2295.414
Enterprise Value/EBITDA -1.669

Trading Information

Paradigm Biopharmaceuticals Stock Price History

Beta (5Y Monthly) 1.140996
52-Week Change -22.68%
S&P500 52-Week Change 20.43%
52 Week High 1.36 USD
52 Week Low 0.61 USD
50-Day Moving Average 0.68 USD
200-Day Moving Average 0.91 USD

PBIGF Share Statistics

Avg. Volume (3 month) 517 USD
Avg. Daily Volume (10-Days) 0 USD
Shares Outstanding 282.09M
Float 240.52M
Short Ratio N/A
% Held by Insiders 16.46%
% Held by Institutions 19.20%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends June 30, 2022
Most Recent Quarter (mrq) December 31, 2022
Next Fiscal Year End June 30, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -137597.26%
Gross Margin -107.73%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -42.70%
Return on Equity (ttm) -69.72%

Income Statement

Revenue (ttm) 38.73K USD
Revenue Per Share (ttm) 0 USD
Quarterly Revenue Growth (yoy) -89.60%
Gross Profit (ttm) -64527 USD
EBITDA -53284852 USD
Net Income Avi to Common (ttm) -44131976 USD
Diluted EPS (ttm) -0.11
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 83.93M USD
Total Cash Per Share (mrq) 0.3 USD
Total Debt (mrq) 389.78K USD
Total Debt/Equity (mrq) 0.53 USD
Current Ratio (mrq) 5.892
Book Value Per Share (mrq) 0.261

Cash Flow Statement

Operating Cash Flow (ttm) -33231114 USD
Levered Free Cash Flow (ttm) -22377408 USD

Profile of Paradigm Biopharmaceuticals

Country United States
State VIC
City Melbourne
Address 500 Collins Street
ZIP 3000
Phone 61 3 9629 5566
Website https://www.paradigmbiopharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees N/A

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Q&A For Paradigm Biopharmaceuticals Stock

What is a current PBIGF stock price?

Paradigm Biopharmaceuticals PBIGF stock price today per share is 0.17 USD.

How to purchase Paradigm Biopharmaceuticals stock?

You can buy PBIGF shares on the Other OTC exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Paradigm Biopharmaceuticals?

The stock symbol or ticker of Paradigm Biopharmaceuticals is PBIGF.

Which industry does the Paradigm Biopharmaceuticals company belong to?

The Paradigm Biopharmaceuticals industry is Biotechnology.

How many shares does Paradigm Biopharmaceuticals have in circulation?

The max supply of Paradigm Biopharmaceuticals shares is 391.92M.

What is Paradigm Biopharmaceuticals Price to Earnings Ratio (PE Ratio)?

Paradigm Biopharmaceuticals PE Ratio is now.

What was Paradigm Biopharmaceuticals earnings per share over the trailing 12 months (TTM)?

Paradigm Biopharmaceuticals EPS is -0.15 USD over the trailing 12 months.

Which sector does the Paradigm Biopharmaceuticals company belong to?

The Paradigm Biopharmaceuticals sector is Healthcare.